New Oncaspar formulation recommended for approval in Europe

The medical panel of the European Medicines Agency has recommended approving lyophilized Oncaspar (pegaspargase) as a component of antineoplastic combination therapy in acute lymphoblastic leukemia (ALL).

The proposed indication covers pediatric patients from birth to 18 years, and in adult patients.

Lyophilized Oncaspar is a freeze-dried formulation. The liquid form is already approved in this indication.

Oncaspar is developed and marketed by Shire.